Overview

Dose-finding Study of MCI-196

Status:
Terminated

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

The Primary Objective of this study is to determine the initial starting doses of colestilan (MCI-196) in paediatric subjects with Chronic Kidney Disease Stage 5 on Dialysis and with Hyperphosphataemia.

Phase:

Phase 3

Details

Lead Sponsor:

Mitsubishi Tanabe Pharma Corporation

Treatments:

Bile Acids and Salts